Drug interactions
Erdafitinib + Lorlatinib
Severity: Moderate
Erdafitinib and Lorlatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib induces CYP3A and may reduce erdafitinib exposure, which is cleared by CYP2C9 and CYP3A4. The reduction may lower antitumor efficacy.
What this interaction means in plain words
Erdafitinib and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Erdafitinib belongs to Oncology; Lorlatinib belongs to Oncology.
Why it happens
Lorlatinib induces CYP3A4, increasing part of erdafitinib metabolism.
What to do
Avoid if possible. If combined, monitor for reduced response and consider erdafitinib phosphate and tolerability guidance in labeling.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Erdafitinib and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Other interactions of Erdafitinib
Frequently asked questions
Can I take Erdafitinib with Lorlatinib?
MediHelp rates the interaction as moderate. Erdafitinib and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib induces CYP3A and may reduce erdafitinib exposure, which is cleared by CYP2C9 and CYP3A4. The reduction may lower antitumor efficacy.
How serious is the interaction between Erdafitinib and Lorlatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid if possible. If combined, monitor for reduced response and consider erdafitinib phosphate and tolerability guidance in labeling.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
